Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.78

€0.78

-1.010%
-0.008
-1.010%
-
 
22.02.24 / Stuttgart Stock Exchange WKN: A14SVV / Name: Sensorion SA / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Sensorion SA Stock

A loss of -1.010% shows a downward development for Sensorion SA.

Pros and Cons of Sensorion SA in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sensorion SA vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sensorion SA -1.010% 4.122% 62.786% 156.721% 95.750% -61.045% -
Cerenis Therapeutics Holding S.A. -8.320% -10.642% -9.881% -42.749% -14.123% 17.686% 151.905%
Genoway S.A. Inh. 0.770% -2.716% -2.716% 1.809% -10.658% 8.840% 52.124%
Hybrigenics S.A. 58.420% 44.144% 39.130% -74.843% -15.344% -92.677% -87.879%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-07

Upon initial review of Sensorion SA's financial statements and accompanying data, one notices a company deeply embedded in the typical patterns of biotechnology and medical research sector, characterized by significant research and development costs and fluctuations in financial health over time. The financials exhibit a pattern that is not out of the ordinary for an entity within this innovative yet unpredictable industry, given the nature of long-term investments into R&D and the regulatory hurdles faced before commercialization can occur. Let's delve into a thorough examination of the strengths and weaknesses as presented by the financials.

High Research & Development Expenditure: Sensorion SA appears steadfast in its commitment to R&D, with the figures illustrating a heavy reinvestment into the development of their biotechnological offerings. This is potentially indicative of a robust pipeline of products that could lead to profitability in the future.

Solid Cash Reserves: Throughout the years, the company has maintained a commendable level of cash and cash equivalents, ensuring that they have a buffer to support ongoing operations and investments.

Comments

Buy Sensorion SA
Show more

News

Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing

Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within